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Fragile X syndrome (FXS) is the most common cause of inherited intellectual
disability and a variant of autism spectrum disorder (ASD). The FXS population
is quite heterogeneous with respect to comorbidities, which implies the need for
a personalized medicine approach, relying on biomarkers or endophenotypes to
guide treatment. There is evidence that quantitative electroencephalography (EEG)
endophenotype-guided treatments can support increased clinical benefit by considering
the patient’s neurophysiological profile. We describe a case series of 11 children
diagnosed with FXS, aged one to 14 years, mean 4.6 years. Case data are based on
longitudinal clinically-observed reports by attending physicians for comorbid symptoms
including awake and asleep EEG profiles. We tabulate the comorbid EEG symptoms in
this case series, and relate them to the literature on EEG endophenotypes and associated
treatment options. The two most common endophenotypes in the data were diffuse
slow oscillations and epileptiform EEG, which have been associated with attention and
epilepsy respectively. This observation agrees with reported prevalence of comorbid
behavioral symptoms for FXS. In this sample of FXS children, attention problems were
found in 37% (4 of 11), and epileptic seizures in 45% (5 of 11). Attention problems were
found to associate with the epilepsy endophenotype. From the synthesis of this case
series and literature review, we argue that the evidence-based personalized treatment
approach, exemplified by neurofeedback, could benefit FXS children by focusing on
observable, specific characteristics of comorbid disease symptoms.
Keywords: fragile X syndrome, electroencephalography, clinical case series, endophenotype, attention deficit
disorder, neurofeedback
INTRODUCTION
Fragile X syndrome (FXS) is the etiology of autism in 2–6% of all children diagnosed with autism
spectrum disorder (ASD) (Dölen and Bear, 2009). FXS is also the most common inherited cause
for intellectual disability ranging from mild to severe (Fisch et al., 2002). The phenotype of FXS
includes distinct behavioral features that often disturb the normal daily life (Smith et al., 2012; Kidd
et al., 2014). Themost common behavioral problem in children with FXS is hyperactivity. Attention
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deficit hyperactivity disorder (ADHD) is diagnosed in
approximately 70–80% of individuals with FXS (Baumgardner
et al., 1995) whereas between 30 and 50% of individuals with
ASD manifest ADHD particularly at pre-school age. FXS
children who display hyperactivity tend to improve with age, and
hyperactivity usually resolves by late adolescence, but attention
problems often persist. A subpopulation around 30% of FXS
individuals meet the criteria for ASD regarding communication
difficulties, such as gaze avoidance, stereotypic and repetitive
behavior, sensory abnormalities, and social anxiety (Hagerman
et al., 2010). Aggressive behavior is more often problematic in
adolescence and adulthood than in childhood and it can be
difficult to handle. Obsessive-compulsive behavior is a common
problem in FXS and it involves both children and adults.
Epilepsy is found in 4–44% of FXS individuals (Kluger et al.,
1996; Sabaratnam et al., 2001; Berry-Kravis, 2002; Louhivuori
et al., 2009). Thus, symptomology arising from comorbidities
may in fact be a considerable contributor to everyday distress for
FXS individuals and difficulty for their caretakers.
Nowadays, no specific therapy is available for FXS.
Nevertheless, successful treatment of comorbidities could
alleviate symptoms non-specific to FXS, facilitating quality of
life. There are various interventions that can be helpful and
usually different interventions work synergistically (Hagerman
et al., 2009). The responses to drug treatment vary and individual
responses are sometimes unpredictable, particularly at young
ages. Furthermore, effects of drug interventions in the immature
brain are not well-understood, emphasizing the need for new
effective treatment approaches without side-effects (Frye et al.,
2013). The FXS population is quite heterogeneous with respect to
comorbidities, which implies that: (a) the approach to each case
should be personalized using validated methods; and (b) it may
be practical to not (or not only) rely on standard treatments, but
also to include non-drug treatments which can be tailored to each
case. Personalized treatment emphasizes heterogeneity within
a given disorder, relying on biomarkers or endophenotypes
to guide different treatments, and can also help the subgroup
of non-responders to traditional treatments. Johnstone et al.
(2005) have argued in support of the personalized treatment
approach for neuropsychiatric syndromes, suggesting “increased
clinical benefit by considering the patient’s neurophysiological
profile.” They suggest that the application of quantitative
electroencephalography (qEEG) analysis can help improve the
objectivity of prescriptions for psychoactive medication, and
the specificity of non-drug treatments such as neurofeedback
(NFB). They suggest that treatments of many kinds can be
guided by EEG profiles which are “manifestations seen between
genome and behavior” that they term “intermediate” EEG
endophenotypes. The approach of linking genes and behavior
via EEG has since been pursued in diverse fields; as Porjesz
and Rangaswamy state “brain oscillations provide a rich source
of potentially useful endophenotypes for psychiatric genetics”
(Porjesz and Rangaswamy, 2007).
Our motivating hypothesis is that: EEG endophenotypes as
described in the literature are evident in FXS children and
can therefore guide personalized treatment and improve disease
understanding. We report a longitudinal case series of children
diagnosed with FXS, including clinically-described EEG profiles.
We collate the comorbid EEG symptoms in this case series,
and relate them to the literature on EEG endophenotypes
and associated NFB treatment options (Johnstone et al.,
2005). Synthesizing the insights from the case series and
literature review, we observe a relation between epileptiform-
symptoms and EEG-indications of attention problems. Thus,
the data suggest that the evidence-based personalized treatment
approach, exemplified by NFB, could benefit FXS cases by
focusing on observable, specific characteristics of comorbid
disease symptoms.
MATERIALS AND METHODS
Altogether 11 Finnish children (ten males and one female,
identified herein by numbers 1–11: female case id= 9; male cases
1–8, 10–11) were included in the case series. Cases were selected
from among a total of 23 children diagnosed with FXS at Kuopio
University Hospital in a 10 years period. Selection criteria were:
(i) the presence of EEG recordings, of which there were 12 cases;
(ii) the presence of EEG abnormality, true for 92% (11 of 12). The
children without any EEG, or without EEG abnormality, are not
reported here.
All subjects participated voluntarily in the experiment, and
a written informed consent was obtained from a parent of the
child. The study was approved by the local Ethics Committee, and
followed the guidelines of the Declaration of Helsinki. Since some
children were measured at multiple times, we report the range of
age at measurement, as 1–14 years, mean = 6 years. The longest
gap between two consecutive measurements for one child was 7
years; the shortest was 4 months.
Case data reported here are based on the longitudinal
clinically-observed reports of attending physicians, for comorbid
symptoms including awake and asleep EEG profiles. Symptoms
of comorbidities, including attention and motor problems, and
epilepsy, were coded as binary variables to indicate presence or
absence. See Table 1 for details.
EEG recordings were performed as clinically required:
for both waking and sleeping protocols, across one or
more measurement points. Clinical EEG experts assessed the
recordings for markers of abnormality and the recordings
were coded at each observation point for the present analysis,
0= normal, 1=mildly abnormal, 2= abnormal.
To estimate the prevalence in the sample of endophenotypic
patterns (also coded as binary variables—see Table 1), the clinical
record of the EEG findings were compared with the literature on
EEG endophenotypes (Johnstone et al., 2005). The estimate was
based on comparison of verbal descriptions (not the normative
database procedure). To analyze patterns in the group data,
we calculated Pearson product moment correlation coefficient,
two-tailed.
RESULTS
EEG Recordings
Clinician classification of the 11 cases by level of abnormality is
given as follows:
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TABLE 1 | Abridged findings from clinical observation notes for waking EEG and comorbidities.
id # Age Abn. EEG findings AP MP Epi. Drug
1 1 41 2 Occipital: strong rhythmical alpha activity 6–8Hz at 100µV, decreases during eyes-open;
Slow wave activity: increases twice, probably due to decrease in alertness;
Paroxysmal transients: spike-slow wave components and sharp waves, spread frontal to
convex, irritable cortex
0 0 0 N
2 45 2 Occipital: strong rhythmical 7–8Hz alpha-activity at 100µV;
Slow wave activity: increases with decreased alertness
1 0 0 N
2 1 24 1 Occipital: strong rhythmical activity 5.5–6Hz at 140µV, decreases when eyes are
opened;
Beta: some mild activity interfered with other activity
0 0 1 N
3 1 40 2 Occipital: strong symmetrical rhythmical activity 7–8Hz at 70µV;
Paroxysmal transients: right (occasionally also left) centro-parietal spikes and spike-slow
wave activity, reflected to dorsal temporal region, irritable cortex;
Slow wave activity: increased in the same areas
1 0 0 N
2 51 2 Occipital: strong rhythmical theta activity 6–7Hz;
Paroxysmal transients: right (occasionally also left) occipital spike-slow wave activity;
Spike-slow wave components are seen to spread over convexity
1 0 0 N
3 61 2 Occipital: strong rhythmical symmetrical activity 8–9Hz at 70µV;
Paroxysmal transients: frontal and occipital spikes and spike-slow wave activity
1 0 1 V
4 68 2 Occipital: 8Hz activity;
Paroxysmal transients: left occipital spikes and spike-slow wave activity;
Right centro-parietal independent irritable activity
1 0 1 V
4 1 60 2 Occipital: rhythmical 7–8.5Hz activity;
Slow wave activity: normal diffuse;
Paroxysmal transients: right dorsal temporo-parietal focal spikes, blinking increases
intensity
1 1 0 N
2 68 2 Occipital: rhythmical 6.5–8.5Hz at 120µV activity, slightly left-asymmetric;
Slow wave activity: strong diffuse;
Paroxysmal transients: spike-slow wave polymorphic activity in delta-range in right
occipital areas, on the left theta
1 1 0 N
5 1 12 1 Occipital: strong rhythmical 4.5Hz activity, delta asymmetry, higher amplitude on the right;
Delta, theta: strong activity on the background; Beta: in the frontal region;
0 1 0 N
6 1 60 1 Slow wave activity: right fronto-temporal bilateral delta frequency discharges;
Paroxysmal transients: left centro-temporal small sharp waves and spikes; no
abnormalities
0 0 1 V
7 1 12 0 Occipital: rhythmical symmetrical 5Hz activity;
Beta: low in all channels;
Slow wave activity: diffuse background activity, appropriate to the age
0 0 0 N
2 21 0 Occipital: rhythmical 5–6Hz at 140µV activity;
Slow wave activity: no change
0 0 0 N
3 36 0 Occipital: rhythmical 5–6Hz at 130µV activity;
Beta: normal in all channels;
Slow wave activity: no change
0 0 0 A
4 72 1 Occipital: rhythmical symmetrical slow activity 5.5–7Hz at 150µV;
Slow wave activity: diffuse background activity increases
0 0 1 C
8 1 81 2 Occipital: labile broken rhythm 6.5–9Hz;
Theta: diffuse activity in excess; Beta: interfered with other activity;
Paroxysmal transients: right temporo-parietal intermittent spikes; spikes and 2–3Hz slow
waves spread over convexity, irritable cortex
0 1 1 C
2 132 2 Occipital: labile broken symmetrical rhythm 8–9Hz at 60µV;
Slow wave activity: in excess;
Paroxysmal transients: right frontal slow waves. Irritable cortex not observed
0 1 1 C
(Continued)
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TABLE 1 | Continued
id # Age Abn. EEG findings AP MP Epi. Drug
9 1 85 1 Occipital: rhythmical 8–10Hz at 160µV activity;
Delta: dorsal region high-amplitude transients; Theta: diffuse, appropriate to the age
Beta: especially in the frontal regions;
0 1 0 N
2 168 0 Occipital: rhythmical 8–9Hz at 90µV activity;
Beta: normal
Paroxysmal transients: individual transients;
0 1 0 N
10 1 63 2 Occipital: rhythmical 7–8Hz at 80µV activity;
Beta: low in all channels;
Paroxysmal transients: left dorso-temporal spikes and spike-slow wave activity, reflected
to the right and occasionally transient over convexity, irritable cortex
1 1 0 C
11 1 59 2 Occipital: rhythmical 6–8Hz at 100µV activity;
Paroxysmal transients: right occipital delta transients; centro-temporal focal spikes
0 0 0 N
Columns, from left to right, are: subject id; number of the measurement; age (in months at measurement); estimate of EEG abnormality (0 = normal, 1 = mild, 2 = abnormal); EEG
findings; AP, attention problems (0 = not observed, 1 = present); MP, motor problems (0 = not observed, 1 = present); Epi., epilepsy symptoms (0 = no, 1 = yes); drug treatment (no
long-term treatment = N, valproate = V, carbamazepine = C, antibiotics = A).
• One girl (case 9) transitioned from “mildly abnormal” to
“normal EEG,” after maturation from 7 to 14 years old.
• One boy (case 7) transitioned from “normal EEG” in three
measurements over 1, 2, and 3 years old, to “mildly abnormal”
after measurement at 6 years.
• One boy (case 8) transitioned from “abnormal EEG” at age
seven to “mildly abnormal” age 11.
• Three boys (cases 2, 5, 6) were classified as “mildly abnormal.”
• Five boys (cases 1, 3, 4, 10, 11) were classified as “abnormal
EEG.”
Waking EEG findings are described in abridged form in Table 1.
There were two main patterns (endophenotypes) in waking EEG
recordings, each with N = 7 (see Table 1). These include
slowing of background rhythm (“diffuse slow” endophenotype)
and epileptiform discharges (“epileptiform” endophenotype).
Other less frequent findings include focal abnormalities,
mixed fast and slow rhythms, excess beta, and generally low
magnitudes.
Most of the correlations between EEG features and symptoms
of comorbidity were only moderate and non-significant. The
highest correlations were between attention problems and EEG
abnormality (Pearson’s r = 0.4, ns); and between attention
problems and the “epileptiform” endophenotype (Pearson’s r =
0.3, ns). The “diffuse slow” type did not correlate strongly with
any behavioral comorbidities. Assessing the correlations within
the set of EEG features, the “epileptiform” endophenotype is the
clear main influence on EEG abnormality, Pearson’s r = 0.9,
significant at p < 0.00001, df = 19, t = 10.
Main findings from sleep EEG included that for two cases
(Kluger et al., 1996; Dölen and Bear, 2009) the waking EEG
abnormalities were no longer present; they were present in cases
2, 3, 5, 6, 8, 9, 10, 11 (case 4 not recorded in sleep) – see Table 2.
For these cases, twomain findings in sleep are that irritable cortex
was observed to increase (case 3, 8), and spike or slow-wave
discharges showed asymmetrically (case 2, 6, 6, 10).
Clinical Observations
Clinical observations are described in abridged form in Table 1.
All children with FXS displayed mild to moderate developmental
delay that associated with difficulties in language development.
Attention problems were observed in four FXS children (cases
1, 3, 4, 10). Symptoms of epilepsy including clinical seizures
combined with EEG abnormalities were observed in five children
(cases 2, 3, 6, 7, 8). Seizures that associated with fever and
infections appeared at younger ages (1.5 and 2 years old in two
FXS boys) than non-febrile seizures which were seen at the age of
4–5.6 years. In agreement with previous reports, epileptic seizures
were complex partial or secondarily generalized. Furthermore,
all five FXS males with epilepsy responded well to treatment
with carbamazepine or valproate, which reduced EEG findings
for three, and normalized the EEG for one boy. One FXS
boy was treated with carbamazepine at age 5 years because of
electrographic abnormalities that associated with restlessness and
anxiety. The treatment alleviated his symptoms.
Based on the clinical reports of EEG, we estimated the
prevalence of the EEG endophenotypes (Johnstone et al., 2005)
for the 11 cases, see Table 3. The EEG observations of these
11 cases follow an expected pattern for the FXS, with a
high prevalence of the “1.diffuse slow” and “7.epileptiform”
endophenotypes. In the “diffuse slow” type (Johnstone et al.,
2005), an increase in slow activity and a decrease in mean
frequency of alpha indicate decreased activation level in brain
which is often seen in pervasive developmental disorders,
dementing illness, and other disorders of consciousness. Notably,
the four FXS children who were noted to have problems with
attention were classified to “epileptiform” type.
DISCUSSION
The present results highlight the heterogeneity of the clinical
phenotype as well as the EEG profile in FXS. Table 3 illustrates a
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TABLE 2 | Abridged clinical observations of sleep EEG (where performed, e.g., case id = 4 was not recorded at all, cases 1, 9 only at second
measurement).
id # age Sleep EEG
1 2 45 Normal sleep-EEG; When alertness is decreased the rhythmical activity of the back areas is desynchronized and slow wave activity is increased;
During sleep sharp K-complexes, vertex-waves and sleep-spindles; the findings made in wake-EEG are not seen here
2 1 24 When the alertness is decreased the rhythmical activity of the back areas is desynchronized and diffuse theta and delta-activity can be seen; During
sleep K-complexes, vertex-waves and sleep-spindles; Also left frontal (as compared to right) slow wave discharges (theta-delta, high in amplitude)
are potentiated in sleep
3 1 40 Central vertex-potentials and sleep-spindles
2 51 Abnormal sleep-EEG; Irritable findings are present and even increased during sleep and especially spike-slow wave components are seen spread
over convexity
3 61 Abnormal sleep-EEG; K-complexes; Irritable findings are increased during sleep
5 1 12 K-complexes and sleep-spindles; Occipital delta asymmetry, higher amplitude on the right
6 1 60 Especially during sleep left middle temporal small sharp waves and spikes
7 1 12 Slow-wave activity increase in sleep; During sleep K-complexes, vertex-waves and sleep-spindles
3 36 During sleep vertex-waves
4 72 Slow-wave activity increases in sleep; During sleep K-complexes, vertex-waves and sleep-spindles
8 1 81 Abnormal sleep-EEG; Irritable findings are increased in sleep (10 s each, with 10–20 s intervals); A lot of rhythmical delta activity (2.5Hz) in the right
hemisphere
9 2 168 Theta paroxysms and increase in diffuse theta during the decrease in alertness
10 1 63 During sleep left dorso-temporal spikes, vertex-waves and sleep-spindles
11 1 59 During sleep K-complexes, vertex-waves and sleep-spindles; Centro-temporal focal spikes
TABLE 3 | EEG endophenotypes (Johnstone et al., 2005), and prevalence
in the sample population as estimated from clinical observations.
# EEG biomarker Case matches
1 Diffuse slow activity, with or without low frequency alpha 1, 2, 3, 4, 5, 7, 11
2 Focal abnormalities, not epileptiform 6
3 Mixed fast and slow 5, 8
4 Frontal lobe disturbances
5 Frontal Asymmetries
6 Excess temporal lobe alpha
7 Epileptiform 1, 3, 4, 6, 8, 10, 11
8 Faster alpha variants, not low voltage
9 Spindling excessive beta 9
10 Generally low magnitudes (fast or slow) 10
11 Persistent alpha with eyes open
mainly bimodal distribution of EEG endophenotypes across the
cases; the primary modes are “diffuse slow” and “epileptiform.”
Four cases shared these two endophenotypes. The correlations
between abnormal EEG, “epileptiform” endophenotype and
attention problems were marginally significant before multiple
comparison correction1, indicating a trend that incidence and
1Naturally at this sample size, p-value statistical testing is somewhat
underpowered.
degree of epileptic EEG relates to attention problems in FXS. The
phenomenon may also be related to the observation of abnormal
attention-cued ERPs, specifically increased N1 amplitude and
power to auditory standards compared with healthy controls
(Castrén et al., 2003).
FXS is a monogenic syndrome that is caused by a mutation
in the FMR1 gene leading to the absence of the FMR1 protein.
FMR1 protein is needed for normal maturation of synapses
and neuronal circuit formation. Its absence results in hyper-
excitability of neocortical circuits and alterations of network
synchrony in brain of FXS mouse model (Gibson et al., 2008;
Gonçalves et al., 2013). Similarly, defects of neuronal connections
and disturbed inhibitory and excitatory balance have been
implicated in infantile autism.
Genetic heterogeneity contributes to the FXS phenotype
and incidence of co-morbidities, including ADHD which
has a heterogeneous background. There is evidence that
the serotonin transporter (5-HTTLPR) genotype modulates
the aggressive, destructive, and stereotypic behavior of FXS
individuals whereas monoamine oxidase A (MAOA-VNTR)
polymorphisms correlate with the consumption of drugs that
regulate serotonin reuptake (Hessl et al., 2008). In Finland, where
fragile X chromosomes show a major haplotype, epilepsy was
found to associate with polymorphisms in the gene for brain-
derived neurotrophic factor in a subpopulation of FXS men
(Louhivuori et al., 2009). Epileptic seizures in FXS show an
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age-related appearance in the childhood or young adulthood and
are less common in adults. The developmental nature of epilepsy
could reflect maturation deficits of the brain and be related to
increased heterogeneity of the EEG profiles in childhood.
Epileptic seizures in FXS are usually easily treatable with
traditional anti-epileptic drugs (AEDs) and the treatment is
recommended based on several retrospective studies (Frye et al.,
2013). However, the effects of AEDs on behavioral and cognitive
symptoms in FXS and ASD have not been systematically studied.
Our present finding, that the attention problems were associated
with the epileptic EEG endophenotype, suggests that treatment
helpful for seizures could be beneficial for the attention problems
in FXS. There is evidence that certain AEDs could be appropriate
to treat seizures of certain individuals with ASD (Frye et al.,
2013), but there are no well-controlled clinical trials to support
the effectiveness and efficacy of AEDs in ASD. Also, Frye et al.
(2013) illustrate that all AEDs indicated for seizures in ASD have
a considerable number of potential side-effects. For example,
of the treatments for cases described here, valproate associates
with hepatotoxicity, thrombocytopenia, hyperammonemia, and
alopecia whereas carbamazepine associates with dizziness, ataxia,
nausea, and hyponatremia. For NFB there are no side effects
reported (Frye et al., 2013).
Ultimately the problem with AEDs is lack of specificity. Even
in this small cohort sampled from a relatively homogenous
population, heterogeneity of symptoms is high. No EEG
endophenotype is dominant; rather the distribution is quite
bimodal. The variation in disabilities is high. We propose that
evidence from EEG data of FXS cases firstly indicates NFB
training for specific relief of comorbid symptoms, and secondly
provides a strong foundation for further studies to more fully
characterize the neural profiles of the disorder at the whole brain
level, by probing the relationship between brain and behavior
using NFB. We elaborate these two arguments in the next two
sections.
EEG Phenotypes and Neurofeedback in
FXS
NFB, also called EEG biofeedback, is operant conditioning of
specific temporal, spatial and frequency features extracted from
scalp-recorded electrical potentials (Lubar and Shouse, 1976).
Literature supports the efficacy of NFB for children with ADHD
(Arns et al., 2009, 2014; Micoulaud-Franchi et al., 2014), and with
epilepsy (Sterman, 2000). The effect of NFB for ASD has not been
so well-studied. Multiple individual case studies or case series
have been reported, and a small number of group studies (Frye
et al., 2013; Pineda et al., 2014). Coben et al. (2010) concluded
a recommendation of “possibly efficacious,” though based on
only two group studies. A more recent and systematic review by
Frye et al. (2013) on treatments for seizures in ASD, found that
NFB had a grade of recommendation of B for “seizures,” B for
“behavioral and cognitive ASD symptoms,” and C for “ASD with
seizures,” with no adverse effects reported2. They characterize
2The classification levels B, C are defined as follows (for full details of the
scheme see Frye et al.): B - At least one study of type: “1b Prospective high-
quality randomized controlled trial (RCT),” “2a systematic review (SR) of cohort
NFB as “a safe treatment that uses operant conditioning to
increase coherence between seizure prone and non-seizure prone
brain regions.” An earlier review by Holtmann et al. (2011)
suggested that, while “existing evidence does not support the use
of [NFB] in the treatment of ASD,” it is possible that studies might
be showing an improvement in comorbid ADHD symptoms,
rather than core ASD symptoms. This latter point supports our
thesis that NFB for FXS comorbidities is indicated.
Part of its value is that NFB can be personalized to suit the
specific clinical presentation, provided that there is requisite
theoretical and observational data to guide the personalization.
Although earlier work (Lubar and Shouse, 1976; Monastra et al.,
2005), including meta-analysis by Snyder and Hall (Snyder and
Hall, 2006), has shown support for a single-trait model of
ADHD (an elevated theta-beta ratio), others have argued that
research results and clinical application should be interpreted
in a more specific way (Arns et al., 2008). Hammond (2010)
goes into this issue in detail, illustrating the heterogeneity in
qEEG patterns associated with symptoms and discussing the
requirements and need for qEEG analysis guided by normative
databases. Johnstone et al. (2005) provide a review of such
databases, along with a review of qEEG endophenotypes, which
we have associated with FXS cases above.
EEG endophenotypes have been shown to have predictive
value for disease assessment. For example, Fonseca et al.
(Fonseca, 2008) found that ADHD children (N = 30) had
significantly greater diffuse slow-frequency power than age-
and sex-matched controls. Chabot et al. (1996) found that a
qEEG-based discriminant function approach to identify ADHD
from normal and learning difficulty children, had specificity and
sensitivity around 90%. EEG endophenotypes are also predictive
for treatment outcome, as shown by Arns et al. (2008) in a study
of ADHD children (N = 49) on stimulants.
We observed two particular EEG endophenotypes in this
case series. A strong relationship between the “epileptoform”
endophenotype and the occurrence of attention problems suggest
that the treatment of this endophenotype (described by e.g.,
Johnstone et al., 2005) may be indicated in FXS. In the suggested
treatment approach (Johnstone et al., 2005), NFB training is
targeted to reduce overall slow wave activity and increase sensory
motor rhythm in the same site as the location of the seizure
onset. This protocol aims to lower cortical hyper-excitability by
reducing a key trigger for sharp waves.
Endophenotype Exploration in FXS
Our suggestion is to more fully characterize the neural profiles of
FXS at the whole brain level, by probing the relationship between
brain and behavior during NFB. The basic concept is to use NFB
for neurophenomenology, as suggested by Bagdasaryan and Van
Quyen (2013), and link neural activity to attention in a causally
closed loop.
(prospective, non-randomized) studies with homogeneity,” or “3a SR of case-
control (retrospective) studies with homogeneity”; or two studies of type: “2b
Individual cohort (prospective, non-randomized) study or low-quality RCT” or
“3b Individual case-control (retrospective) study.”
C - At least one study of type: “2b” or “3b”; or two studies of type: “case series or
reports.”
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The motivation stems from the fact that FXS is genetically
well-characterized, whereas e.g., ADHD is not. As Gevensleben
et al. (2014) argue, efficacy of NFB is hard to assess without a
proper model of specific effects of treatment. Further, Zuberer
et al. (2015) argue that such a model should be tested by
examination of the neurological data corresponding to operant
conditioning progress, i.e., learning curves. However, in the
neuropsychiatric disorders commonly treated by NFB, the
etiology of the disorder is often not known, or unclear. This
makes it hard to interpret the data.
The approach may be better supported by the well-
characterized monogenic disease model such as FXS, which
also appears to have clearly expressed EEG endophenotypes
within the group. With a well-defined disease model, a clear
endophenotype, and sufficiently well-prepared neurological and
behavioral data on learning and expectations, there is an
opportunity to accurately relate the treatment to the observed
effects. The opportunity also meets a clinical need based on the
estimation that in spite of the good supporting evidence for
treating seizures and ASD, prevalence of use of NFB is less than
1% (Frye et al., 2013).
Gevensleben and colleagues describe two polar models for the
application of NFB, the “conditioning and repairing” model and
the “skill acquisition” model. Conditioning and repairing refers
to normalization of a well-defined “specific neurophysiological
deficit” by implicit learning, while skill acquisition refers
to explicit learning of self-regulation, potentially by anyone
regardless of neurological health.While FXS individuals certainly
possess the specific neurophysiological deficit, the FXS condition
itself is not a viable target for “normalization,” and the target
of treatment is thus the complex range of comorbidities. As
Gevensleben et al. points out “Complex attentional and social
behaviors (encompassing different top-down and bottom-up
mechanisms) rely to a larger extent on self-regulation skills and
will not change to a clinically significant level due to distinct
neurophysiological changes alone but have to be addressed on
different levels. Neurophysiological changes must spread out
beyond NFB-trained neuronal circuits and be accompanied by
changes in cognitive-behavioral patterns to achieve enhanced
self-regulation in complex environments.”
The research strategy we propose is to separate the treatment
by contiguous conditions in a way that “normalization” training
takes place before “self-regulation” training. A similar approach
has been recently piloted (Cowley et al., 2016). The effects
due to each condition can be observed in isolation and in the
context of the well-defined theoretical model of NFB and a
well-characterized disease model.
CONCLUSION
In this paper we have described the clinical and EEG
symptoms of 11 diagnosed FXS cases. We assessed the EEG
symptoms in terms of the literature on EEG endophenotypes,
and found that “epileptiform”-like symptoms are associated
with attention problems in these cases. We then developed
the argument that specific treatment for EEG symptoms is
indicated.
The brain has an adaptive nature and ability to self-regulate
when receiving feedback (Johnstone et al., 2005). This implies
that the function of NFB to promote self-regulation (Mayer
et al., 2013), (a non-specific effect of the operant conditioning
paradigm), may further benefit treated FXS children’s capacity
to (co)operate in social and educational contexts. NFB is also
marked by a relative ease and flexibility compared tomedications,
since the neurophysiological status is under constant assessment
during treatment, and the protocols can be changed at any time
to respond to the clinical development. Thus, we conclude that
the need exists for a novel line of study, based on clinical trials
of NFB for FXS comorbidities, with the opportunity not only to
test the treatment efficacy but also to establish a more complete
characterization of the behavioral and systems neuroscience of
the disorder and related symptoms.
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